

Anti-p19Arf (exon 1b) (RAT) Monoclonal Antibody - 200-501-892

Coc	de: 200-501-892 Size	: 100 µg	
Product Description:	: Anti-p19Arf (exon 1b) (RAT) Monoclonal Antibody - 200-501-892		
Concentration:	: 1.0 mg/mL by UV absorbance at 280 nm		
PhysicalState:	: Liquid (sterile filtered)		
Label	Unconjugated		
Host	Rat		
Gene Name	CDKN2A		
Species Reactivity	human, mouse, hamster.		
Buffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2		
Stabilizer	None		
Preservative	0.01% (w/v) Sodium Azide		
Storage Condition	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C Avoid cycles of freezing and thawing. Centrifuge product if not completely temperature. This product is stable for several weeks at 4° C as an undilut immediate use.	clear after standing at room	
Synonyms	Cyclin-dependent kinase inhibitor 2A, isoform 3 p19ARF		
Application Note	for western blotting reactivity should be optimized by the end user. Expect	antibody has been tested for use in ELISA, western blotting and immunoprecipitation. Specific conditions estern blotting reactivity should be optimized by the end user. Expect a band approximately 19 kDa in size esponding to mouse p19Arf by western blotting in the appropriate cell line or lysate.	
Background	The Ink4a-Arf locus encodes two tumor suppressor proteins, p16Ink4a and p19Arf. Expression of Ink4a and Arf is regulated by distinct promoters upstream of alternative first exons whose products are spliced to a common becond exon translated in alternative reading frames (from which Arf gets its name). The two genes are induced by different stress signals and can be separately mutated or silenced in tumor cells. Targeted disruption of bither or both genes in mouse leads to spontaneous tumor formation, which is accelerated by exposure of the nutant animals to chemical carcinogens or ionizing radiation. Inactivation of ARF by mutation, deletion, or pigenetic silencing is observed in many human cancers, underscoring the role of this protein as a potent and biquitous tumor suppressor. p19Arf is activated by Myc or mutant Ras. Once activated, p19Arf binds to the 153 negative regulator Mdm2, leading to p53 stabilization and unleashing a p53-dependent transcriptional program that triggers either cell cycle arrest or apoptosis. p19Arf also has p53-independent inhibitory effects on tell proliferation. p19Arf is a nucleolar protein and is implicated in ribosomal biogenesis.		
Purity And Specificity	This is a Protein G purified antibody directed against mouse p19Arf protein human or hamster homologues. The epitope was putatively mapped to am BLAST analysis indicates that no significant sequence homology exists for homologues from other sources. This epitope is also found on mouse p16 information is available for reactivity with p19Arf protein from other sources	hino acids 54-62 of mouse p19Arf. this sequence with p19Arf SInk4a protein. No additional	
Assay Dilutions	User Optimized		
ELISA	1:5,000 - 1:20,000		
WESTERN BLOT	1:500 - 1:2,000		
OTHER ASSAYS	User Optimized		
Expiration	Expiration date is one (1) year from date of opening.		
Immunogen	nis protein G purified monoclonal antibody was produced by repeated immunizations with a synthetic peptide prresponding to amino acid residues 54-75 of mouse p19Arf protein.		
General Reference	Quelle,D.E., Zindy,F., Ashmun,R.A. and Sherr,C.J. (1995) Alternative reac suppressor gene encode two unrelated proteins capable of inducing cell cy	ling frames of the INK4a tumor cle arrest. Cell 83 (6), 993-1000.	
	Serrano, M., Hannon, G. J. & Beach, D. (1993) A new regulatory motif in ce inhibition of cyclin D/CDK4. Nature 366, 704–707.	ell-cycle control causing specific	
	Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmur (1997) Tumor suppression at the mouse INK4a locus mediated by the alter p19ARF. Cell 91, 649–659.	n, R. A., Grosveld, G. & Sherr, C. J. native reading frame product	

Related Products

	200-301-174	Anti-p53 (MOUSE) Monoclonal Antibody - 200-301-174	
	200-501-891	Anti-p19Arf (exon 2) (RAT) Monoclonal Antibody - 200-501-891	
	612-103-120	Anti-RAT IgG (H&L) (GOAT) Antibody Peroxidase Conjugated (Min X Bv Ch Gt GP Ham Hs Hu Ms Rb & Sh Serum Proteins) - 612-103-120	
	B501-0500	BLOTTO Immunoanalytical Grade (Non-Fat Dry Milk) - B501-0500	
Related Links			
	UniProtKB	http://www.uniprot.org/uniprot/Q64364	
	NCBI	http://www.ncbi.nlm.nih.gov/protein/1162947	
	NCBI - 1162947	http://www.ncbi.nlm.nih.gov/protein/1162947	
	UniProt - Q64364	http://www.uniprot.org/uniprot/Q64364	
	Gene ID - 12578	http://www.ncbi.nlm.nih.gov/gene/12578	
Images			
	1	Western blot analysis is shown using Rockland's Protein A Purified Rat Monoclonal Anti-p19Arf antibody to detect mouse p19Arf protein present in p19Arf transformed NIH-3T3 cells. Approximately 30 ?g of cell lysate was loaded on a 4-12% NuPage SDS-PAGE gel using MES buffer. The blot was incubated with a 1:1,000 dilution of the antibody at room temperature followed by washing. A 1:20,000 dilution of HRP conjugated Gt-anti-Mouse IgG preceded color development using Pierce Chemical's SuperSignal substrate. Comparison to a molecular weight marker (not shown) indicates a single band of ~96.0 kDa corresponding to the expected molecular weight for human PMS2 protein. Other detection systems will yield similar results. See Bertwistle et al. 2004 for details).	
96 kDa —	• • • • • • • • • • • • • • • • • • •		
	MA WARNER	- is Short	
	L		

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.